Global Market Research Briefing · 2026 –2035
Sexual Dysfunction Treatment Market From PDE5 volume to telehealth, female indications and device therapy — a USD a USD 24.80 billion absolute dollar opportunity through 2035
$31.80B
$58.40B
6.33%
~39%
Market value, 2025
Forecast value, 2035
CAGR, 2026–2035
North America share, 2025
Investors
Strategy teams
B2B leaders
Sizing, CAGR & ROI signals
Segment & regional priorities
Channel & partner whitespace
Copyright © Next Move Strategy Consulting · Source: NMSC Sexual Dysfunction Treatment Market report
Market Landscape
A USD 31.80B market on track to USD 58.40B by 58.40B by 2035 Global revenue forecast (USD billion)
6.33% CAGR
+USD 24.80B absolute opportunity, 2026–2035
2026–2035
58.40
31.80
2025
33.60
2026
35.73
2027
37.99
2028
40.39
2029
42.95
2030
Executive summary
45.67
2031
48.56
2032
51.63
2033
54.90
2034
2035
Leading shares, 2025
Valued at USD 31.80B (2025) and USD 33.60B (2026); forecast to reach USD 58.40B by 2035. Drug therapy leads with ~78% (USD 24.80B) on PDE5 inhibitor prescription volume.
78%
Male SD holds ~71% (USD 22.58B); female SD is the fastestgrowing indication at 8.2% CAGR.
Drug therapy
North America dominates at ~39% (USD 12.40B); the U.S. alone ≈ USD 10.67B.
by therapy
71%
Male SD
therapy
Telehealth prescribing and declining stigma are reshaping channel economics.
by indication
39%
32%
North America
Hospital pharmacy
America
pharmacy
by region
by channel
INDUSTRY ECOSYSTEM — SEGMENTATION COVERAGE Therapy
Indication
Distribution
End user
Drug therapy
Male SD
Hospital · Retail
Hospitals · Clinics
Device therapy
Female SD
Online · Specialty
ASCs · Home care
Products: PDE5 inhibitors, hormone therapy, PE drugs, penile prostheses, vacuum erection devices
Copyright © Next Move Strategy Consulting · Source: NMSC Sexual Dysfunction Treatment Market report
Growth Drivers & Opportunities
Aging, telehealth and female indications unlock unlock USD 24.80B Impact on CAGR, 2026–2035 (pp)
High-growth segments (CAGR)
Aging-driven ED prevalence
+1.6
Female SD drug approvals
+1.2
Telehealth & online pharmacy
+1.0
Declining treatment stigma
+0.8
Generic PDE5 penetration
+0.6
Diabetes & CVD prevalence
+0.5
Limited reimbursement
−0.7
Female SD underdiagnosis
−0.6
PDE5 safety concerns
−0.4
Driver
9.8%
Online pharmacy
8.3%
Device therapy
8.2%
Female SD
10.9%
India
Fastest channel
Fastest therapy type
Fastest indication
Fastest country
Restraint
Regional growth opportunity map North America — largest region, ~39% 1
2
~39% share (USD 12.40B); U.S. ≈ USD 10.67B Middle East & Africa — fastest-growing growing region at 8.5% CAGR
1
3
~10.9% CAGR Latin America & Asia-Pacific — generic
3
4 2
India — fastest-growing country at ~10.9%
generic PDE5 penetration lowers cost barriers
4
Telehealth-pharmacy partnerships Capture recurring prescriptions from
Underdiagnosed female SD
Outpatient device designs
Clinician education and screening build
Surgeon-training partnerships with
long-term prescribing ties.
ambulatory surgical centers.
patients avoiding in-person visits.
USD 24.80B
Absolute dollar opportunity, 2026–2035 — highest attractiveness for players combining drug and device capability with telehealth distribution reach.
Copyright © Next Move Strategy Consulting · Source: NMSC Sexual Dysfunction Treatment Market report
Competitive Scenario
A moderately consolidated market with high, access-led rivalry Competitive positioning matrix
Porter's Five Forces
Branded pharma innovators Pfizer
Eli Lilly
Device & novel-format specialists
Generic / cost-led → Branded / innovation-led
Coloplast
Futura Medical
Ferring
Generic volume producers
White space
Viatris
Low-cost, outpatient-compatible
Teva
Sun Pharma
Mod–High
Supplier power
Moderate
Buyer power
Moderate
New entrants
Low
How players compete
devices for ASCs; device therapy grows Cipla
Threat of substitutes
Petros Pharma Laborie
Takeda
High
Organon
Boston Scientific Sprout Pharma
Competitive rivalry
Zydus
Endo
Clinical-trial evidence strength Prescriber-relationship depth
grows fastest at 8.3% CAGR
Channel breadth incl. online Telehealth-partnership integration
Drug therapy focus → Device therapy focus
Key strategic moves — M&A, expansion, partnerships Apr 2026
M&A
Jul 2026
Expansion
2025
Partnership
Sun Pharma agrees to acquire Organon for
Futura Medical's Eroxon® now in 27
Viatris broadens generic PDE5 access via
Organon for USD 11.75B, expanding
markets after EU launch clearance.
via telehealth-pharmacy tie-ups.
women's health.
2025
Product
2025
DTC
2025
Awareness
Boston Scientific refines its inflatable
Eli Lilly sustains direct-to-consumer
Sprout expands flibanserin awareness
penile prosthesis platform.
investment for its ED portfolio.
awareness campaigns in female SD.
17 leading verified providers Pfizer
Eli Lilly
Boston Scientific
Coloplast
Ferring
Petros
Futura Medical
Takeda
Structure: moderately consolidated
Viatris
Teva
Endo
Organon
Sprout
Sun Pharma
Cipla
Laborie
Innovation: female SD, telehealth, outpatient devices
M&A: specialty pharma & device consolidation
Copyright © Next Move Strategy Consulting · Matrix is a qualitative view based on NMSC competitive archetypes
Zydus
Let's Connect
Thank You Connect with our analysts for in-depth segment, regional and competitive insights — and strategic guidance tailored to your investment or growth agenda.
W ebsi t e
P hone
E m ai l
www.nextmsc.com
+1 857 758 5017
info@nextmsc.com
Click here for the complete report
→
FO L L O W U S
YouTube
Sexual Dysfunction Treatment Market — Global Industry Analysis and Forecast, 2026–2035
Copyright © Next Move Strategy Consulting